SCHEMBL11951242

SCHEMBL11951242

O=C(N[C@H](Cc1ccccc1)C(=O)O)c1sc2cc(F)ccc2c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR3 O15455 1/20 1.00
SENP1 Q9P0U3 1/20 0.61
PRNP P04156 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
BCKDK O14874 1/20 0.55
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
MAPT P10636 2/20 0.52
HPGD P15428 1/20 0.52
SCN3A Q9NY46 1/20 0.50
NPC1 O15118 3/20 0.48
TSHR P16473 1/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
RECQL P46063 1/20 0.47
PTGS1 P23219 1/20 0.45
MAOB P27338 1/20 0.45
CASP3 P42574 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11951244 1.00 TLR3 (1.00) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11301956 1.00 TLR3 (1.00) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11298597 0.92 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11950492 0.92 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11950491 0.92 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11500750 0.91 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11951271 0.91 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11300435 0.91 TLR3 (0.84) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11498991 0.89 TLR3 (0.80) TLR3SENP1PRNPNPSR1RXFP1
SCHEMBL11950554 0.89 TLR3 (0.80) TLR3SENP1PRNPNPSR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025030019-A1 TARGETING TLR3 FOR TREATMENT OF HEMATOPOIETIC STEM CELL PROLIFERATION-ASSOCIATED DISEASES OR DISORDERS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-02-06 WO claimed
US-20250011869-A1 TLR3 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION HOLFELD, Johannes (AT) 2025-01-09 US claimed
EP-4419098-A2 TLR3 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION Holfeld, Johannes (AT) 2024-08-28 EP claimed
WO-2023066949-A2 MATERIALS AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, PROPHYLAXIS AND TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION HOLFELD JOHANNES (AT) 2023-04-27 WO claimed
WO-2025030019-A1 TARGETING TLR3 FOR TREATMENT OF HEMATOPOIETIC STEM CELL PROLIFERATION-ASSOCIATED DISEASES OR DISORDERS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-02-06 WO disclosed
US-20250011869-A1 TLR3 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION HOLFELD, Johannes (AT) 2025-01-09 US disclosed
EP-4419098-A2 TLR3 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION Holfeld, Johannes (AT) 2024-08-28 EP disclosed
WO-2023066949-A2 MATERIALS AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, PROPHYLAXIS AND TREATMENT OF DISEASES ASSOCIATED WITH CARDIOVASCULAR CALCIFICATION HOLFELD JOHANNES (AT) 2023-04-27 WO disclosed
CN-105251006-B Purposes of the TLR3 inhibitor in the drug for preparing treatment cocaine habituation 四川大学 2018-08-03 CN disclosed
US-9409880-B2 Modulators of TLR3/dsRNA complex and uses thereof THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2016-08-09 US disclosed
US-9409880-B2 Modulators of TLR3/dsRNA complex and uses thereof THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2016-08-09 US disclosed
US-9409880-B2 Modulators of TLR3/dsRNA complex and uses thereof THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2016-08-09 US disclosed
WO-2012099785-A2 MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2012-07-26 WO disclosed